Factor Xa Inhibitors: Mechanisms, Clinical Complications and Advances in Reversal Strategies

Keerti Chakravarthy

Factor Xa Inhibitors

Factor Xa inhibitors are a type of anticoagulant that prevent blood clotting by inhibiting the activity of factor Xa, a crucial enzyme in the coagulation process. The factor Xa inhibitors include:

- Apixaban
- Betrixaban
- Edoxaban
- Rivaroxaban



Mechanisms of Actions

- Factor Xa inhibitors exert their efforts by directly and specifically inhibiting factor Xa by competitively blocking its activity.
- The clotting cascade can typically be defined by 3 steps: Initiation, Propagation, and Fibrin formation.



Apixaban (Eliquis)

- **Indication:**
  - Approved for nonvalvular AF
  - Management of DVT and PE
  - VTE prophylaxis post hip or knee replacement
- **Complication:** commonly causes bleeding.
- **Side effects:**
  - Common: nausea, gum bleeding, blood in urine, heavy periods, anemia, bruising, hematomas, and post-procedural bleeding.
  - Others are: rectal bleeding, nosebleeds, coughing up blood, and elevated liver enzymes.
  - Rarely, hypersensitivity reactions occur.
- The FDA advises against its use in patients with prosthetic heart valves.

Betrixaban (Bevyxxa)

- **Indication:**
  - Prophylaxis of VTE in adults
  - Preventing strokes in patients with nonvalvular AF
  - VTE prophylaxis following hip or knee replacement
- **Complication:** Bleeding
  - Typically mild, but can be life-threatening bleeding,
    - Patients receiving neuraxial anesthesia or spinal puncture due to risk of spinal/epidural hematomas.
- **Side effect:** Bleeding is the most frequently reported adverse effect. While most cases are mild, serious or life-threatening bleeding can occur.

Edoxaban (Lixiana)

- **Indication:**
  - Therapeutic intervention for DVT and PE
  - Prevention of stroke and systemic embolism in patients with nonvalvular AF
- **Dosage:** once-daily anticoagulant
- **Side effects:**
  - Spinal/epidural hematomas, severe bleeding, thrombocytopenia, angioedema, and increased clot risk if stopped; milder effects include bleeding, anemia, rashes, and elevated liver enzymes
  - Bleeding risk rises with concurrent use of aspirin, antiplatelets, or fibrinolytics.

Rivaroxaban

- **Indication:**
  - Prevention of DVT after joint replacement, reduce stroke risk in nonvalvular AF, treat and prevent VTE, lower risk after ACS or PAD, and prevent clots in hospitalized patien with acute illness
  - Off-label, rivaroxaban is used for treating heparin-induced thrombocytopenia , post-stent placement in AF, and for acute superficial vein thrombosis.
- **Dosage:** once-daily anticoagulant
- **Side effects:**
  - Bleeding is the most common side effect, ranging from mild to life-threatening, especially in high-risk patients.
  - Other effects include dizziness, fatigue, pain, and skin reactions. Rare but serious reactions include allergic responses, liver injury, and severe skin conditions like Stevens-Johnson syndrome.



Andexanet Alfa

–Approved in 2018

–Recombinant modified FXa decoy

- Ability to reverse effects of both direct and indirect FXa inhibitors
- No intrinsic catalytic activity

–Coagulation tests normalized: chromogenic anti-Xa

- Test not readily available

–Reversal of apixaban and rivaroxaban





Mechanism of Action

–Inactive recombinant factor Xa molecule

- Binds to factor Xa antagonist, preventing binding to active factor Xa

Dosing and Administration

- 100 mg or 200 mg vials (lyophilized powder)
- **Low dose:** 400 mg IV bolus + 480 mg IV infusion
- **High dose:** 800 mg IV bolus + 960 mg IV infusion → approximately 9–18 vials total depending on dose

Andexanet Alfa is a Specific Reversal Agent that Binds and Sequesters FXa inhibitors, Therefore Restoring Native Fxa activity



Broad spectrum Reversal Agents: Ciraparantag

- Underdevelopment
- Mechanism of Action
  - Binds and removes the anticoagulant from thrombin (factor IIa) and factor Xa
    - Potential to reverse dabigatran, oral factor Xa antagonists, heparin, and low-molecular-weight heparin
- Available Data
  - Healthy volunteer, dose ranging study
  - Ciraparantag reversed the effect of edoxaban on whole blood clotting time
    - Within 10 minutes of administration
    - Persistent reversal over 24-hour evaluation period
  - Well tolerated, dose between 100 mg and 300 mg IV push



4 Factor PCC's

- Pharmacologic blood factor products
  - 4-factor prothrombin complex concentrates (PCC, Kcentra)
  - –Activated PCC (aPCC, FEIBA)
  - –Recombinant factor VII (NovoSeven)
- Only option prior to the availability of specific reversal agents
  - Extremely limited data – case report, retrospective studies, healthy volunteer or in vitro studies
    - Improved coagulation lab values
  - Off-label use
  - Theoretical prothrombotic risk – black box warning
- Expert consensus statements for reversal of DOACs
  - FEIBA 25–50 units/kg
  - 4-factor PCC 50 units/kg

Analysis of Study

Background: FXa inhibitor-related bleeding is challenging; andexanet alfa (AA) was added to a hospital guideline alongside 4F-PCC.

Objective: Evaluate the use and effectiveness of AA vs. 4F-PCC after guideline implementation.

Methods:

- Retrospective, multi-hospital study (Oct 2018–June 2020)
- 85 adult patients needing urgent reversal of FXa inhibitor-induced bleeding

Primary outcome: hemostatic efficacy

Secondary outcomes: thromboembolism, blood product use, ICU/hospital stay, mortality

Results: Hemostasis achieved in:

AA: 84.8% **4F-PCC:** 76.9% **Thrombotic events higher with AA** (18% vs. 3.8%)

No significant differences in other secondary outcomes

Conclusion:

- Both agents had similar effectiveness in bleeding control
- AA was associated with more thrombotic events
- Larger prospective studies are needed for further evaluation

Conclusion

In summary, Factor Xa inhibitors represent a significant advancement in anticoagulation therapy, offering effective prevention and treatment of thromboembolic disorders with more predictable pharmacokinetics and fewer monitoring requirements compared to traditional agents like warfarin. While their benefits are clear, it is important to remain aware of their associated bleeding risks and the evolving strategies for reversal, especially in emergency settings. As clinical use continues to grow, staying informed about guideline updates and reversal options like andexanet alfa and 4-factor PCCs is essential for optimizing patient care and safety.

Acknowledgements

I would like to thank Dr. Siddiqui and Dr. Fareed for their mentorship throughout this internship. I would also like to thank the Board of GTF for extending this opportunity towards me. Lastly, I would like to thank my parents for their support.

References

Agrawal, A., Kerndt, C. C., & Manna, B. (2024, February 22). *Apixaban*. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK507910/

Baker, D. E. (2017). Formulary Drug review: Betrixaban. *Hospital Pharmacy*, *53*(1), 29–37. https://doi.org/10.1177/0018578717739397

Padda, I. S., & Chowdhury, Y. S. (2023, August 25). *Edoxaban*. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK565876

Siddiqui, F., Hoppensteadt, D., Jeske, W., Iqbal, O., Tafur, A., & Fareed, J. (2019). Factor Xa Inhibitory profile of apixaban, betrixaban, edoxaban, and rivaroxaban does not fully reflect their biologic spectrum. *Clinical and Applied Thrombosis/Hemostasis*, *25*. https://doi.org/10.1177/1076029619847524

Singh, R., & Emmady, P. D. (2023, April 17). *Rivaroxaban*. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557502/